References
  1. Abbayya K, Puthanakar NY, Naduwinmani S, Chidambar YS. Association between Periodontitis and Alzheimer’s Disease. N Am J Med Sci. 2015 Jun;7(6):241-6.
  2. Demmer RT, Holtfreter B, Desvarieux M, Jacobs DR Jr, Kerner W, Nauck M, Völzke H, Kocher T. The influence of type 1 and type 2 diabetes on periodontal disease progression: prospective results from the Study of Health in Pomerania (SHIP). Diabetes Care  2012: 35: 2036–2042.
  3. Eke PI, Wei L, Borgnakke WS, Thornton-Evans G, Zhang X, Lu H, McGuire LC, Genco RJ. Periodontitis prevalence in adults ≥ 65 years of age, in the USA. Periodontol 2000. 2016 Oct;72(1):76-95.
  4. Kassebaum NJ, Bernabe E, Dahiya M, Bhandari B, Murray CJL, Marcenes W. Global burden of severe periodontitis in 1990–2010: a systematic review and meta-regression. J Dent Res 2014: 93: 1045–1053.
  5. Robert A Whittington, Emmanuel Planel, Niccolo Terrando. Impaired Resolution of Inflammation in Alzheimer’s Disease: A Review. Front. Immunol. 2017; 8:2017.
  6. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement  (2007) 3:186–91.
  7. Luo H, Pan W, Sloan F, Feinglos M, Wu B. Forty-year trends in tooth loss among American adults with and without diabetes mellitus: an age-period-cohort analysis. Prev Chronic Dis 2015: 12: E211.
  8. Ma KS, Hasturk H, Carreras I, Dedeoglu A, Veeravalli JJ, Huang JY, et al. Dementia and the risk of periodontitis: a population-based cohort study. J Dent Res. 2022;101(3):270–7.
  9. Ryder, M.I. The Link Between Periodontitis and Alzheimer’s Disease: Reality or Yet Another Association. Curr Oral Health Rep  9 , 157–166 (2022).
  10. Leblhuber, F., Huemer, J., Steiner, K. et al.  Knock-on effect of periodontitis to the pathogenesis of Alzheimer’s disease?. Wien Klin Wochenschr  132 , 493–498 (2020).
  11. Wang, R.PH., Huang, J., Chan, K.W.Y. et al.  IL-1β and TNF-α play an important role in modulating the risk of periodontitis and Alzheimer’s disease. J Neuroinflammation  20 , 71 (2023).
  12. Azizi G, Mirshafiey A. The potential role of proinflammatory and antiinflammatory cytokines in Alzheimer disease pathogenesis. ImmunopharmacolImmunotoxicol. 2012; 34:881–95.
  13. Azizi G, Navabi SS, Al-Shukaili A, Seyedzadeh MH, Yazdani R, Mirshafiey A. The Role of Inflammatory Mediators in the Pathogenesis of Alzheimer’s Disease. Sultan Qaboos Univ Med J. 2015 Aug;15(3): e305-16.
  14. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol. 2007;7:161–7.
  15. Varatharaj A, Galea I. The blood-brain barrier in systemic inflammation. Brain Behav Immun. 2017; 60:1–12.
  16. Gorlovoy P, Larionov S, Pham TT, Neumann H. Accumulation of tau induced in neurites by microglial proinflammatory mediators. FASEB J. 2009;23:2502–13
  17. Gorlovoy P, Larionov S, Pham TT, Neumann H. Accumulation of tau induced in neurites by microglial proinflammatory mediators. FASEB J. 2009;23:2502–13
  18. Lin X, Bai G, Lin L, Wu H, Cai J, Ugen KE, et al. Vaccination-induced changes in pro-inflammatory cytokine levels as an early putative biomarker for cognitive improvement in a transgenic mouse model for Alzheimer’s disease. Hum VaccinImmunother. 2014;10:2024–31.
  19. Koyama A, O’Brien J, Weuve J, Blacker D, Metti AL, Yaffe K. The role of peripheral inflammatory markers in dementia and Alzheimer’s disease: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2013;68(4):433–40.
  20. Holmes C, El-Okl M, Williams AL, Cunningham C, Wilcockson D, Perry VH. Systemic infection, interleukin 1β, and cognitive decline in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2003;74(6):788–9.
  21. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 2009;73(10):768.
  22. Detrait ER, Danis B, Lamberty Y, Foerch P. Peripheral administration of an anti-TNF-α receptor fusion protein counteracts the amyloid induced elevation of hippocampal TNF-α levels and memory deficits in mice. Neurochem Int. 2014;72(1):10–3.
  23. Paul Oindrila, Arora Payal, Mayer Michael, Chatterjee Shampa. Inflammation in Periodontal Disease: Possible Link to Vascular Disease.Frontiers in Physiology 2021;11:2020.
  24. Graves DT, Cochran D. The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. J Periodontol. 2003 Mar;74(3):391-401.
  25. Nikolopoulos GK, Dimou NL, Hamodrakas SJ, Bagos PG. Cytokine gene polymorphisms in periodontal disease: a meta-analysis of 53 studies including 4178 cases and 4590 controls. J Clin Periodontol. 2008 Sep;35(9):754-67.
  26. Preshaw PM, Taylor JJ. How has research into cytokine interactions and their role in driving immune responses impacted our understanding of periodontitis? J Clin Periodontol. 2011;38:60–84.
  27. Park KM, Bowers WJ. Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal.  2010;22:977–83.
  28. Montgomery SL, Bowers WJ. Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system. J Neuroimmune Pharmacol.  2012;7:42–59.
  29. Lee KS, Chung JH, Choi TK, Suh SY, Oh BH, Hong CH. Peripheral cytokines and chemokines in Alzheimer’s disease. Dement Geriatr Cogn Disord.  2009;28:281–7.
  30. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nature reviews Immunology. 2008;8(5):349–361
  31. Kourtzelis I, Mitroulis I, von Renesse J, Hajishengallis G, Chavakis T. From leukocyte recruitment to resolution of inflammation: the cardinal role of integrins. Journal of leukocyte biology. 2017;102:677–683.
  32. Ortega-Gomez A, Perretti M, Soehnlein O. Resolution of inflammation: an integrated view. EMBO molecular medicine. 2013;5(5):661–674.
  33. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510(7503):92–101.
  34. Serhan CN, Chiang N. Resolution phase lipid mediators of in‐ flammation: agonists of resolution. Curr Opin Pharmacol. 2013;13(4):632‐640.
  35. Perretti M, Leroy X, Bland EJ, Montero‐Melendez T. Resolution pharmacology: opportunities for therapeutic innovation in inflam‐ mation. Trends Pharmacol Sci. 2015;36(11):737‐755.
  36. Serhan CN, Chiang N, Dalli J. New pro‐resolving n‐3 mediators bridge resolution of infectious inflammation to tissue regeneration. Mol Aspects Med. 2018;64:1‐17.
  37. m DS. Omega-3 fatty acids in anti-inflammation (pro-resolution) and GPCRs. Prog Lipid Res 2012; 51: 232-7.
  38. Ryan A, Godson C. Lipoxins: regulators of resolution. Curr Opin Pharmacol 2010; 10: 166-72.
  39. Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M, Serhan CN, Murphy PM. International union of basic and clinical pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev 2009; 61: 119-61.
  40. Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R, Petasis NA, Serhan CN. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A 2010; 107: 1660-5.
  41. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev 2011; 111: 5922-43.
  42. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007; 447: 869-74.
  43. Hong S, Lu Y. Omega-3 fatty acid-derived resolvins and protectins in inflammation resolution and leukocyte functions: targeting novel lipid mediator pathways in mitigation of acute kidney injury. Front Immunol 2013; 4: 13.
  44. Medeiros R, Kitazawa M, Passos GF, Baglietto-Vargas D, Cheng D, Cribbs DH, et  al. Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice. Am J Pathol (2013) 182:1780–9.
  45. Dunn HC, Ager RR, Baglietto-Vargas D, Cheng D, Kitazawa M, Cribbs DH, et  al. Restoration of lipoxin A4 signaling reduces Alzheimer’s disease-like pathology in the 3xTg-AD mouse model. J Alzheimers Dis (2015) 43:893–903.
  46. Takano T, Fiore S, Maddox JF, Brady HR, Petasis NA, Serhan CN. Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J Exp Med (1997) 185:1693–704
  47. Torres M, Price SL, Fiol-Deroque MA, Marcilla-Etxenike A, Ahyayauch H, Barcelo-Coblijn G, et  al. Membrane lipid modifications and therapeutic effects mediated by hydroxydocosahexaenoic acid on Alzheimer’s disease. Biochim Biophys Acta (2014) 1838:1680–92.
  48. Teng E, Taylor K, Bilousova T, Weiland D, Pham T, Zuo X, et  al. Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and Abeta pathology and modulates Abeta oligomerization. Neurobiol Dis (2015) 82:552–60.
  49. Hosono T, Mouri A, Nishitsuji K, Jung CG, Kontani M, Tokuda H, et al. Arachidonic or docosahexaenoic acid diet prevents memory impairment in Tg2576 mice. J Alzheimers Dis (2015) 48:149–62.
  50. Darveau, R. P. (2010). Periodontitis: a polymicrobial disruption of host homeostasis. Nat. Rev. Microbiol.  8, 481–490
  51. Michlewska, S., Dransfield, I., Megson, I. L., and Rossi, A. G. (2009). Macrophage phagocytosis of apoptotic neutrophils is critically regulated by the opposing actions of pro-inflammatory and anti-inflammatory agents: key role for TNF-alpha. FASEB J.  23, 844–854.
  52. Cochrane (2008). New cochrane systematic reviews — cochrane oral health group. J. Evid. Based Dent. Pract.  8, 258–260.
  53. Maria Balta, Bruno G. Loos, Elena A. Nicu. Emerging Concepts in the Resolution of Periodontal Inflammation: A Role for Resolvin E1. Front. Immunol.2017,8:1682.